• Revenues up 19% to $3.4 million
• Net loss increased to $2.1 million due to administration costs
• Successful completion of corporate restructuring and capital initiatives

Epsilon Healthcare Limited reported a net loss after income tax of $2,068,860 for the half-year ended 30 June 2025, compared to a loss of $1,438,889 in the prior corresponding period. Revenues from continuing operations increased by 19% to $3,401,788, driven by work to build new client engagements and rebuild existing client relationships. The introduction of the new Epsilon Pharmacy business segment also contributed to the improved revenue performance. The increase in net loss was primarily attributable to administrator's fees, interest and loan charges associated with financing activities, as well as $561,000 in fees incurred for remediation work. The Group achieved substantial progress in restoring stability and clarity to its corporate structure, with the effectuation of Deeds of Company Arrangement for its key subsidiaries. This marks an important step forward in strengthening the Group's foundation and supporting renewed confidence in its future direction.Epsilon Healthcare also successfully advanced its capital initiatives, issuing $555,000 of loan notes that were converted to 27,750,000 shares. Additionally, the company completed a strategic $6.7 million sale and leaseback transaction of its manufacturing property, which was used to extinguish debt and provide working capital.The company's securities remain suspended from quotation on the ASX pending compliance with ASX requirements, with the Board undertaking remedial actions to address matters raised by the ASX.